92 related articles for article (PubMed ID: 15467619)
1. A new assay to screen for head and neck squamous cell carcinoma using the tumor marker metallopanstimulin.
Lee WJ; Keefer K; Hollenbeak CS; Stack BC
Otolaryngol Head Neck Surg; 2004 Oct; 131(4):466-71. PubMed ID: 15467619
[TBL] [Abstract][Full Text] [Related]
2. Metallopanstimulin as a novel tumor marker in sera of patients with various types of common cancers: implications for prevention and therapy.
Fernandez-Pol JA
Anticancer Res; 1996; 16(4B):2177-85. PubMed ID: 8694540
[TBL] [Abstract][Full Text] [Related]
3. Metallopanstimulin as a marker for head and neck cancer.
Stack BC; Hollenbeak CS; Lee CM; Dunphy FR; Lowe VJ; Hamilton PD
World J Surg Oncol; 2004 Dec; 2():45. PubMed ID: 15598348
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
5. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia.
Almadori G; Bussu F; Galli J; Cadoni G; Zappacosta B; Persichilli S; Minucci A; Giardina B; Maurizi M
Cancer; 2005 Jan; 103(2):284-92. PubMed ID: 15593092
[TBL] [Abstract][Full Text] [Related]
7. Identification of patients with head and neck cancer using serum protein profiles.
Wadsworth JT; Somers KD; Stack BC; Cazares L; Malik G; Adam BL; Wright GL; Semmes OJ
Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):98-104. PubMed ID: 14732777
[TBL] [Abstract][Full Text] [Related]
8. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma.
Kim CH; Lee JS; Kang SO; Bae JH; Hong SP; Kahng H
Oral Oncol; 2007 Nov; 43(10):1021-5. PubMed ID: 17306605
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
10. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH
J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374
[TBL] [Abstract][Full Text] [Related]
11. Head and neck squamous cell carcinoma: measurement of plasma parathyroid hormone-related protein and serum and urine calcium concentrations.
Sellers RS; Schuller DE; Sharma PK; Tannehill-Gregg SH; Capen CC; Rosol TJ
Otolaryngol Head Neck Surg; 2000 Nov; 123(5):558-62. PubMed ID: 11077340
[TBL] [Abstract][Full Text] [Related]
12. Proteomic identification of serum biomarkers for head and neck cancer surveillance.
Gourin CG; Zhi W; Adam BL
Laryngoscope; 2009 Jul; 119(7):1291-302. PubMed ID: 19444892
[TBL] [Abstract][Full Text] [Related]
13. Plasma osteopontin is an independent prognostic marker for head and neck cancers.
Petrik D; Lavori PW; Cao H; Zhu Y; Wong P; Christofferson E; Kaplan MJ; Pinto HA; Sutphin P; Koong AC; Giaccia AJ; Le QT
J Clin Oncol; 2006 Nov; 24(33):5291-7. PubMed ID: 17114663
[TBL] [Abstract][Full Text] [Related]
14. Extraribosomal function of metallopanstimulin-1: reducing paxillin in head and neck squamous cell carcinoma and inhibiting tumor growth.
Dai Y; Pierson SE; Dudney WC; Stack BC
Int J Cancer; 2010 Feb; 126(3):611-9. PubMed ID: 19642098
[TBL] [Abstract][Full Text] [Related]
15. Quantification of p38αMAP kinase: a prognostic marker in HNSCC with respect to radiation therapy.
Gill K; Mohanti BK; Ashraf MS; Singh AK; Dey S
Clin Chim Acta; 2012 Jan; 413(1-2):219-25. PubMed ID: 21982916
[TBL] [Abstract][Full Text] [Related]
16. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
[TBL] [Abstract][Full Text] [Related]
17. Serum protein profile analysis in patients with head and neck squamous cell carcinoma.
Gourin CG; Xia ZS; Han Y; French AM; O'Rourke AK; Terris DJ; Adam BL
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):390-7. PubMed ID: 16618908
[TBL] [Abstract][Full Text] [Related]
18. Salivary soluble CD44: a potential molecular marker for head and neck cancer.
Franzmann EJ; Reategui EP; Carraway KL; Hamilton KL; Weed DT; Goodwin WJ
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):735-9. PubMed ID: 15767360
[TBL] [Abstract][Full Text] [Related]
19. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation.
Yang MH; Chiang WC; Chou TY; Chang SY; Chen PM; Teng SC; Wu KJ
Clin Cancer Res; 2006 Jan; 12(2):507-15. PubMed ID: 16428493
[TBL] [Abstract][Full Text] [Related]
20. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma.
Gourin CG; Moretz WH; Weinberger PM; Xia ZS; Liu Z; Terris DJ; Adam BL
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1125-30. PubMed ID: 18025317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
